CurrentCignaPolicy IP0376

Vyvgart Intravenous (efgartigimod alfa-fcab) — Coverage Criteria

Defines Cigna prior authorization, coverage criteria, dosing, and excluded uses for Vyvgart IV in adults with anti‑AChR antibody‑positive generalized myasthenia gravis.

Policy Summary

PayerCigna

PolicyVyvgart Intravenous (efgartigimod alfa-fcab) — Coverage Criteria

Policy CodePolicy IP0376

Change TypeMaterial updates to dosing frequency and exclusionsdocumentation clarified

Effective Date

Next Review Date

Key ActionObtain prior authorization and submit documentation confirming anti‑AChR antibody‑positive status and prior pyridostigmine use or documented intolerance.

SourceLink

POLICY UPDATE CHANGES

Removed the requirement that treatment cycles are no more frequent than every 50 days from the start of the previous treatment cycle; dosing guidance now states subsequent treatment cycles are administered based on clinical evaluation.

Documentation instructions were expanded to explicitly include prescription receipts as acceptable documentation.

Concomitant use exclusion was expanded to explicitly include Uplizna (inebilizumab-cdon) and additional examples of neonatal Fc receptor blockers and complement inhibitor biosimilars.

6 monthsapproval duration (initial)

1 yearapproval duration (continuing)

≥5MG-ADL threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial Therapy (6 months)

Approve for 6 months if ALL of the following are met:

Initial Therapy - all required: Patient is ≥ 18 years of age; confirmed anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (documentation required); meets BOTH: Myasthenia Gravis Foundation of America (MGFA) class II–IV AND MG-ADL score ≥ 5; has received or is currently receiving pyridostigmine OR has had inadequate efficacy, a contraindication, or significant intolerance to pyridostigmine; has evidence of unresolved symptoms of generalized myasthenia gravis (examples: difficulty swallowing, difficulty breathing, or functional disability such as double vision, impaired speech, or impaired mobility); medication is prescribed by or in consultation with a neurologist.

Patient Currently Receiving Vyvgart (1 year)

Approve for 1 year if ALL of the following are met:

Currently Receiving - all required: Patient is ≥ 18 years of age; per prescriber, patient is continuing to derive clinical benefit from Vyvgart Intravenous (or Vyvgart Hytrulo); medication is prescribed by or in consultation with a neurologist.

Dosing

Approve if the patient meets ONE of the following dosing regimens:

Dosing option A: Patient weighs < 120 kg: 10 mg/kg administered by intravenous infusion once weekly for 4 weeks (each infusion over approximately one hour).

Dosing option B: Patient weighs ≥ 120 kg: 1,200 mg administered by intravenous infusion once weekly for 4 weeks.

Retreatment guidance: Subsequent treatment cycles administered based on clinical evaluation (no fixed frequency requirement).

Vyvgart Intravenous is not medically necessary for uses outside the approved indication of anti‑AChR antibody‑positive generalized myasthenia gravis. Specifically, concomitant administration of Vyvgart with another neonatal Fc receptor (FcRn) blocker, a complement inhibitor, a rituximab product, or Uplizna (inebilizumab‑cdon) is excluded because there is no evidence to support combined use. Examples called out in the policy include neonatal Fc receptor blockers such as Imaavy (nipocalimab‑aahu), Rystiggo (rozanolixizumab‑noli), and Vyvgart Hytrulo; complement inhibitors such as eculizumab (Soliris) and its biosimilars, Ultomiris (ravulizumab‑cwvz), and Zilbrysq (zilucoplan).

The exclusions list is intended to be comprehensive for concomitant biologic therapies in this policy and may be updated as new data become available. Requests that propose concurrent treatment with these listed agents should be considered not medically necessary and will be denied per the policy language.

Use of Vyvgart Intravenous for indications other than anti‑AChR antibody‑positive generalized myasthenia gravis is considered not medically necessary. The policy requires documentation confirming the approved diagnosis before coverage is granted.

The policy also explicitly prohibits concomitant use with the classes and examples noted above (other FcRn blockers, complement inhibitors including biosimilars to Soliris, rituximab products, and Uplizna). These concomitant‑use prohibitions were recently expanded in the revisions to include additional examples and to align the policy with current prescribing information.

Billing and Coding

Covered HCPCS CodesHCPCSCovered

J9332

Injection, efgartigimod alfa-fcab, 2 mg

Weight-based dosing

Dose for patients < 120 kg10 mg/kg intravenous infusion once weekly for 4 weeks.

Dose for patients ≥ 120 kg1200 mg intravenous infusion once weekly for 4 weeks.

Subsequent treatment cyclesAdminister subsequent treatment cycles based on clinical evaluation (no fixed frequency restriction).

Provider Requirements, Documentation, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior Authorization is required for benefit coverage of Vyvgart Intravenous. Approval is contingent on meeting the clinical criteria (age, antibody status, MG-ADL threshold, and other listed requirements). Approvals are time-limited and may be extended if the patient continues to meet the Criteria and Dosing. Prescriptions must be written by or in consultation with a neurologist or a specialist in the treated condition.

Prior authorization required for Vyvgart Intravenous; approvals depend on meeting policy clinical criteria.
All approvals are provided for the duration specified in the policy; 1 month = 30 days when months are used.
Requests for dosing outside the policy will be reviewed case-by-case by a clinician (Medical Director or Pharmacist).

Step Therapy

Pyridostigmine Trial Expectation

Pyridostigmine is expected to have been received or at least considered before initiating Vyvgart Intravenous unless there is documented inadequate efficacy, a contraindication, or significant intolerance. Documentation of prior trial or rationale for not using pyridostigmine must be provided when required by the criteria.

Clinical Definitions and Outcome Measures

MG-ADL (Myasthenia Gravis Activities of Daily Living)

MeasureMyasthenia Gravis Activities of Daily Living (MG-ADL): an 8-item patient-reported measure assessing impact on daily function; each item scored 0–3, higher total indicates greater impairment.

Policy threshold for treatment initiationMG-ADL total score ≥ 5 is required for initial therapy coverage.

Use in efficacy assessmentUsed as the primary efficacy measure in clinical trials supporting Vyvgart; population studied had MG-ADL ≥ 5.

MG-ADL responder (trial-defined outcome)

Responder definitionAn MG-ADL responder is a patient with a ≥2-point reduction in total MG-ADL score from the treatment cycle baseline for at least 4 consecutive weeks.

Timing requirement

Background

Myasthenia gravis is an autoimmune neuromuscular disorder caused by pathogenic IgG autoantibodies—most commonly anti‑acetylcholine receptor (anti‑AChR) antibodies—that produce fluctuating skeletal muscle weakness worsened by activity. Vyvgart (efgartigimod alfa‑fcab) is a neonatal Fc receptor blocker indicated for adults with anti‑AChR antibody‑positive generalized myasthenia gravis; it reduces pathogenic IgG by blocking IgG recycling via the FcRn, which can lead to clinical improvement in strength and daily function.

In clinical use, Vyvgart Intravenous is dosed according to patient weight and the manufacturer’s guidance (for example, 10 mg/kg IV weekly x4 for patients < 120 kg or a fixed 1200 mg IV weekly x4 for patients ≥ 120 kg), and retreatment frequency is determined by clinical evaluation rather than a fixed interval. The policy was updated to remove a prior stipulation limiting treatment cycles to no more than every 50 days and to state that subsequent cycles are administered based on clinical response and evaluation.